Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02075905 · ClinicalTrials.gov registry record
Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management
A clinical trial of Esophageal Adenocarcinoma and Barrett's Esophagus, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 111
- Enrollment target
- 4
- Study locations
NCT02075905 is a study of Esophageal Adenocarcinoma and Barrett's Esophagus that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 111 participants, below the 306-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (64% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT02075905, a study of Esophageal Adenocarcinoma and Barrett's Esophagus, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 111 participants
- Enrollment target
- 4
- Study locations
Study Summary
Subjects enrolled in this study will have biopsies obtained and sent to Dr. Fitzgerald's lab for analysis of a validated biomarker panel. Subjects will be stratified to either high or low risk of progression to esophageal adenocarcinoma (EAC) based on biomarker panel results. Biomarker panel results will not be communicated to sites. Subjects with low grade dysplasia will be offered the option of treatment (radiofrequency ablation (RFA)) as part of routine care. Subjects with low grade dysplasia who do not want RFA and subjects with no dysplasia will receive surveillance endoscopy in 1 year per routine care. All subjects will be administered a questionnaire seeking information about hypothetical willingness to be randomized to treatment or surveillance.
Conditions Studied
Study Locations (4)
Other
- Academic Medical Center - Amsterdam
- University of Cambridge - Cambridge
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Ohio
- Case Western Reserve University - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02075905
The ClinicalTrials.gov registry entry for NCT02075905 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 306-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (64% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT02075905 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Other, North Carolina, Ohio.
Frequently Asked Questions
What is clinical trial NCT02075905 about?
NCT02075905 is a clinical study titled "Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management". Subjects enrolled in this study will have biopsies obtained and sent to Dr. Fitzgerald's lab for analysis of a validated biomarker panel. Subjects will be stratified to either high or low risk of progression to esophageal adenocarcinoma (EAC) based on biomarker panel results. Biomarker panel results...
What is the current status of trial NCT02075905?
This trial is currently completed. The enrollment target is 111 participants. The study started on 2014-03. Estimated completion is 2015-08.
What conditions does trial NCT02075905 study?
This clinical trial studies the following conditions: Esophageal Adenocarcinoma, Barrett's Esophagus, Dysplasia, Intestinal Metaplasia.
Who is sponsoring clinical trial NCT02075905?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02075905 being conducted?
This trial has 4 study locations across North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING · NA
-
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
RECRUITING
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.